3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hematologic Diseases
1
Granulosa Cell Tumor
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Interventions
Imatinib Mesylate
11
Cyclophosphamide
11
Peripheral Blood Stem Cell Transplantation
9
Cyclosporine
8
fludarabine phosphate
7
Radiotherapy
7
Methotrexate
7
Filgrastim
7
Dasatinib
7
Busulfan
7
Antilymphocyte Serum
7
nilotinib
6
Tacrolimus
6
Mycophenolic Acid
6
Sirolimus
5
Cord Blood Stem Cell Transplantation
5
bosutinib
4
Whole-Body Irradiation
4
Methylprednisolone
4
Melphalan
4
Interferon-alpha
4
ponatinib
3
Alemtuzumab
3
sargramostim
2
Sunitinib
2
Rituximab
2
Moxifloxacin
2
Leucovorin
2
Homoharringtonine
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myeloid, Chronic-Phase
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts